Preparation, characterisation, and pharmacodynamic study of myricetin pH-sensitive liposomes
AIMS: Myricetin (MYR) was incorporated into pH-sensitive liposomes in order to improve its bioavailability and anti-hyperuricemic activity.
METHODS: The MYR pH-sensitive liposomes (MYR liposomes) were prepared using thin film dispersion method, and assessed by particle size (PS), polydispersed index (PDI), zeta potential (ZP), encapsulation efficiency, drug loading, and in vitro release rate. Pharmacokinetics and anti-hyperuricemic activities were also evaluated.
RESULTS: The PS, PDI, ZP, encapsulation efficiency, and drug loading of MYR liposomes were 184.34 ± 1.05 nm, 0.215 ± 0.005, -38.46 ± 0.30 mV, 83.42 ± 1.07%w/w, and 6.20 ± 0.31%w/w, respectively. The release rate of MYR liposomes was higher than free MYR, wherein the cumulative value responded to pH. Besides, the Cmax of MYR liposomes was 4.92 ± 0.20 μg/mL. The level of uric acid in the M-L-H group (200 mg/kg) was reduced by 54.74%w/v in comparison with the model group.
CONCLUSION: MYR liposomes exhibited pH sensitivity and could potentially enhance the oral bioavailability and anti-hyperuricemic efficacy of MYR.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Journal of microencapsulation - (2024) vom: 15. Apr., Seite 1-15 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Li, Chenlu [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-hyperuricemic activity |
|---|
| Anmerkungen: |
Date Revised 15.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1080/02652048.2024.2337461 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371080282 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371080282 | ||
| 003 | DE-627 | ||
| 005 | 20240415234736.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240415s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1080/02652048.2024.2337461 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1376.xml |
| 035 | |a (DE-627)NLM371080282 | ||
| 035 | |a (NLM)38618699 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Li, Chenlu |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Preparation, characterisation, and pharmacodynamic study of myricetin pH-sensitive liposomes |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 15.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a AIMS: Myricetin (MYR) was incorporated into pH-sensitive liposomes in order to improve its bioavailability and anti-hyperuricemic activity | ||
| 520 | |a METHODS: The MYR pH-sensitive liposomes (MYR liposomes) were prepared using thin film dispersion method, and assessed by particle size (PS), polydispersed index (PDI), zeta potential (ZP), encapsulation efficiency, drug loading, and in vitro release rate. Pharmacokinetics and anti-hyperuricemic activities were also evaluated | ||
| 520 | |a RESULTS: The PS, PDI, ZP, encapsulation efficiency, and drug loading of MYR liposomes were 184.34 ± 1.05 nm, 0.215 ± 0.005, -38.46 ± 0.30 mV, 83.42 ± 1.07%w/w, and 6.20 ± 0.31%w/w, respectively. The release rate of MYR liposomes was higher than free MYR, wherein the cumulative value responded to pH. Besides, the Cmax of MYR liposomes was 4.92 ± 0.20 μg/mL. The level of uric acid in the M-L-H group (200 mg/kg) was reduced by 54.74%w/v in comparison with the model group | ||
| 520 | |a CONCLUSION: MYR liposomes exhibited pH sensitivity and could potentially enhance the oral bioavailability and anti-hyperuricemic efficacy of MYR | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a anti-hyperuricemic activity | |
| 650 | 4 | |a bioavailability | |
| 650 | 4 | |a in vitro release | |
| 650 | 4 | |a myricetin | |
| 650 | 4 | |a pH-sensitive liposomes | |
| 700 | 1 | |a Du, Mengzhe |e verfasserin |4 aut | |
| 700 | 1 | |a Meng, Lingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Adu-Frimpong, Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Gong, Caizhi |e verfasserin |4 aut | |
| 700 | 1 | |a Zheng, Sile |e verfasserin |4 aut | |
| 700 | 1 | |a Shi, Wentao |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Qilong |e verfasserin |4 aut | |
| 700 | 1 | |a Toreniyazov, Elmurat |e verfasserin |4 aut | |
| 700 | 1 | |a Ji, Hao |e verfasserin |4 aut | |
| 700 | 1 | |a Cao, Xia |e verfasserin |4 aut | |
| 700 | 1 | |a Yu, Jiangnan |e verfasserin |4 aut | |
| 700 | 1 | |a Xu, Ximing |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of microencapsulation |d 1989 |g (2024) vom: 15. Apr., Seite 1-15 |w (DE-627)NLM013098217 |x 1464-5246 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:15 |g month:04 |g pages:1-15 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1080/02652048.2024.2337461 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 15 |c 04 |h 1-15 | ||